Creation of Novel Antibody Pharmaceuticals through Joint Research with Pharmaceutical Companies and Others

「By promoting joint research and development with other companies, we aim to accelerate the development of our drug discovery programs and expand into new disease areas and modality fields. The joint research with あすか製薬株式会社, which began in November 2025 to create new drugs by applying our proprietary antibody technology, is progressing as planned. In the joint research with Eurus Therapeutics株式会社, which began in December 2025, we confirmed results that led to further progress in obtaining the target antibody and antibody gene. In response, we entered into a new joint research agreement in August 2026 as the next step, advancing the profiling and optimization of the antibody and antibody gene. We also considered joint research with KYORIN Pharmaceutical Co.,Ltd. aimed at creating new drugs using antibody technology. A joint research agreement was subsequently concluded in October 2026.」